$497 Million is the total value of MPM BioImpact LLC's 34 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BDTX | Exit | Black Diamond Therapeutics, Inc. | $0 | – | -144,888 | -100.0% | -0.07% | – |
| AVRO | Exit | AVROBIO, Inc. | $0 | – | -647,918 | -100.0% | -0.17% | – |
| ARQT | Exit | Arcutis Biotherapeutics inc | $0 | – | -254,137 | -100.0% | -0.73% | – |
| TCRR | Exit | TCR2 Therapeutics, Inc. | $0 | – | -3,370,982 | -100.0% | -1.31% | – |
| QURE | Exit | Uniqure N.V. | $0 | – | -348,224 | -100.0% | -1.82% | – |
| INBX | Exit | Inhibrx, Inc Com | $0 | – | -1,192,281 | -100.0% | -5.84% | – |
| PRVB | Exit | Provention Bio Inc | $0 | – | -1,173,809 | -100.0% | -7.35% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.